查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2153397

全球子宮內膜異位症治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Endometriosis Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 218 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球子宮內膜異位症治療市場預計將從2025年的24.9億美元成長至2034年的72.3億美元，2026年至2034年的複合年成長率（CAGR）為12.59%。全球子宮內膜異位症治療市場正經歷顯著成長，這主要歸因於子宮內膜異位症在全球女性的盛行率不斷上升。女性健康意識的提高和診斷技術的進步，使得該疾病能夠被更早發現和及時治療。該市場涵蓋荷爾蒙療法、止痛藥物以及旨在緩解症狀和改善生活品質的外科手術等治療手段。

成長要素包括醫療保健支出增加、微創手術技術的進步以及對新療法的研究不斷深入。製藥公司正投資研發副作用較少的標靶治療。此外，政府的支持和宣傳宣傳活動也鼓勵更多女性尋求醫療保健服務。

未來幾年，創新藥物研發和個人化治療方案有望推動該市場成長。診斷工具的改進和公眾意識的提高將進一步刺激需求。隨著醫療保健系統日益關注女性健康問題，子宮內膜異位症治療市場預計將穩定成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、阻礙因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球子宮內膜異位症治療市場：依治療類型分類

  • 市場分析、洞察與預測
  • 止痛藥
  • 荷爾蒙療法

第5章：全球子宮內膜異位症治療市場：依藥物類別分類

  • 市場分析、洞察與預測
  • NSAIDs
  • 口服避孕藥
  • 促性腺激素分泌釋放激素
  • 其他

第6章：全球子宮內膜異位症治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 注射藥物
  • 其他

第7章：全球子宮內膜異位症治療市場：依分銷管道分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 其他

第8章 全球子宮內膜異位症治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • AbbVie
    • Bayer
    • Pfizer
    • Organon
    • Myovant Sciences
    • Eli Lilly
    • Takeda
    • AstraZeneca
    • Ipsen
    • Ferring Pharmaceuticals
    • ObsEva
    • Debiopharm
    • Neurocrine Biosciences
    • Theramex
    • Richter Gedeon
    • Merck KGaA
    • Evotec
    • Bristol Myers Squibb
    • Mayne Pharma
    • HeraMED
簡介目錄
Product Code: VMR112110345

The global endometriosis treatment market size is expected to reach USD 7.23 Billion in 2034 from USD 2.49 Billion in 2025, growing at a CAGR of 12.59% during 2026-2034.The Global Endometriosis Treatment Market is witnessing significant growth due to the increasing prevalence of endometriosis among women worldwide. Growing awareness about women's health and improved diagnostic techniques are leading to early detection and timely treatment. The market includes hormonal therapies, pain management drugs, and surgical procedures aimed at reducing symptoms and improving quality of life.

Key drivers include rising healthcare spending, advancements in minimally invasive surgeries, and increasing research into new treatment options. Pharmaceutical companies are investing in developing targeted therapies with fewer side effects. Additionally, supportive government initiatives and awareness campaigns are encouraging more women to seek medical care.

In the coming years, the market is expected to benefit from innovative drug development and personalized treatment approaches. Improved diagnostic tools and greater awareness will further boost demand. As healthcare systems focus more on women's health issues, the endometriosis treatment market is projected to grow steadily.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Treatment Type

  • Pain Medication
  • Hormone Therapy

By Drug Class

  • NSAIDs
  • Oral Contraceptive
  • Gonadotropin Releasing Hormone
  • Others

By Route of Administration

  • Oral
  • Injectable
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

COMPANIES PROFILED

  • AbbVie, Bayer, Pfizer, Organon, Myovant Sciences, Eli Lilly, Takeda, AstraZeneca, Ipsen, Ferring Pharmaceuticals, ObsEva, Debiopharm, Neurocrine Biosciences, Theramex, Richter Gedeon, Merck KGaA, Evotec, Bristol Myers Squibb, Mayne Pharma, HeraMED

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL ENDOMETRIOSIS TREATMENT MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Treatment Type
  • 4.2. Pain Medication Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Hormone Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ENDOMETRIOSIS TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Drug Class
  • 5.2. NSAIDs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Oral Contraceptive Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Gonadotropin Releasing Hormone Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ENDOMETRIOSIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Route Of Administration
  • 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ENDOMETRIOSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Distribution Channel
  • 7.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ENDOMETRIOSIS TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Treatment Type
    • 8.2.2 By Drug Class
    • 8.2.3 By Route Of Administration
    • 8.2.4 By Distribution Channel
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Treatment Type
    • 8.3.2 By Drug Class
    • 8.3.3 By Route Of Administration
    • 8.3.4 By Distribution Channel
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Spain
    • 8.3.10 Russia
    • 8.3.11 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Treatment Type
    • 8.4.2 By Drug Class
    • 8.4.3 By Route Of Administration
    • 8.4.4 By Distribution Channel
    • 8.4.5 China
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 India
    • 8.4.9 Australia
    • 8.4.10 South East Asia
    • 8.4.11 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Treatment Type
    • 8.5.2 By Drug Class
    • 8.5.3 By Route Of Administration
    • 8.5.4 By Distribution Channel
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Treatment Type
    • 8.6.2 By Drug Class
    • 8.6.3 By Route Of Administration
    • 8.6.4 By Distribution Channel
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ENDOMETRIOSIS TREATMENT INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 AbbVie
    • 10.2.2 Bayer
    • 10.2.3 Pfizer
    • 10.2.4 Organon
    • 10.2.5 Myovant Sciences
    • 10.2.6 Eli Lilly
    • 10.2.7 Takeda
    • 10.2.8 AstraZeneca
    • 10.2.9 Ipsen
    • 10.2.10 Ferring Pharmaceuticals
    • 10.2.11 ObsEva
    • 10.2.12 Debiopharm
    • 10.2.13 Neurocrine Biosciences
    • 10.2.14 Theramex
    • 10.2.15 Richter Gedeon
    • 10.2.16 Merck KGaA
    • 10.2.17 Evotec
    • 10.2.18 Bristol Myers Squibb
    • 10.2.19 Mayne Pharma
    • 10.2.20 HeraMED